Sang-We Kim

Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

E. Felip, R. Caparica, M. Garassino, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study

Myung-Ju Ahn, Chao-Hua Chiu, S. D. Karam, 2024, Lung Cancer.

Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722

J. Gainor, K. Ichikado, J. Sylvester, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

Mohamed Reda Keddar, P. Jewsbury, D. Morgensztern, 2024, Nature medicine.